Olatoyosi Odenike to Isocitrate Dehydrogenase
This is a "connection" page, showing publications Olatoyosi Odenike has written about Isocitrate Dehydrogenase.
Connection Strength
1.028
-
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
Score: 0.603
-
IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy. Haematologica. 2026 05 01; 111(5):1625-1633.
Score: 0.221
-
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Mol Cell. 2021 09 16; 81(18):3833-3847.e11.
Score: 0.164
-
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 04 01; 137(13):1792-1803.
Score: 0.040